Sumitomo Pharma Co., Ltd.

Industry

  • Distributors
  • Pharmaceuticals
    • Vaccines
  • Digital Health
    • Disease Management

Other Names/Subsidiaries

  • Adagio Pharmaceuticals
  • Altavant Sciences
  • Boston Biomedical
  • Boston Biomedical Pharma
  • Cannasat Therapeutics
  • Cynapsus Therapeutics
  • Dainippon Sumitomo Pharma
  • DS Pharma Promo
  • Elevation Pharmaceuticals
  • Enzyvant Therapeutics
  • Enzyvant Sciences
  • Myovant Sciences
  • Oryx Pharmaceuticals
  • SB Bioscience
  • Spirovant Sciences
  • Sumitomo Chemical
  • Sumitomo Dainippon Pharma
  • Sumitomo Dainippon Pharma America
  • Sumitomo Dainippon Pharma Oncology
  • Sumitomo Pharmaceuticals
  • Sumitomo Pharmaceuticals America
  • Sumitomo Pharmaceuticals Suzhou
  • Sumitovant Biopharma
  • Sunovion Pharmaceuticals
  • Tolero Pharmaceuticals
  • Urovant Sciences.
See more in Biomedtracker

Latest on Sumitomo Pharma Co., Ltd.

Scrip

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Xu Hu

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. SunRock, Escugen Partner To Develo

Scrip

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

 
• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Taiho Sends Benz LSD1 Inhibitor Fo

Scrip

Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Eyenovia, Betaliq Will Have Combined C

Scrip

Kura/Kyowa Kirin’s Ziftomenib Scores In NPM1m AML, But Differentiation Is Key

 
• By Alaric DeArment

Kura Oncology and Kyowa Kirin plan to pursue US Food and Drug Administration approval based on positive Phase II topline results for ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemi